PPI-resistant gastro-esophageal reflux disease
Conditions
Interventions
The subjects take 20 mg of esomeprazole once a day for four weeks.
Sponsors
Division of Gastroenterology, Aichi Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) The study is conducted with the written informed consent of patients who had been given a full explanation of the study. (2)The GERD patients who has taken standard dose PPIs for 8 weeks. (3)The patients who was judged to be insufficient therapeutic response by GerdQ questionnaire.
Exclusion criteria
Exclusion criteria: (1)alarm sign such as vomitting or gastrointestinal bleeding (2)Zollinger Ellison syndrome, esophageal stenosis, achalasia, cerebrovascular disorder (3)Serious hepatic disorder, renal disease, heart disorder (4)malignant disorder (5)A pregnant woman, nursing mother or the woman who may be pregnant. (6)In addition, clinical studies supervisor or the study attending physician judged the subject to be inadequate to attend this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptom, QOL, neurosis evaluation by questionnaire | — |
Secondary
| Measure | Time frame |
|---|---|
| pathophysiology of GERD by 24-hour intraesophageal pH/impedance monitoring, HP infection, gastric mucosal atropy, CYP2C19 genetic polymorphism | — |
Countries
Japan
Contacts
Public ContactKunio Kasugai
Aichi Medical University School of Medicine Gastroenterology
Outcome results
None listed